Neurosense Therapeutics Ltd (NRSNW)
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
📈 **POSITIVE** • Medium confidence analysis (65%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (77%) **Content type:** Clinical